Skip to main content
Spectral Medical Inc. logo

Spectral Medical Inc. — Investor Relations & Filings

Ticker · EDT ISIN · CA8475771033 LEI · 529900085WMSYNZ2SM78 TSX Manufacturing
Open in API
Filings indexed 292 across all filing types
Latest filing 2026-04-01 Regulatory Filings
Country CA Canada
Listing TSX EDT

About Spectral Medical Inc.

https://spectraldx.com/

Spectral Medical Inc. is a late-stage theranostic company focused on developing and commercializing products for the treatment of endotoxic septic shock (ESS). The company employs a unique theranostic approach that pairs a diagnostic test with a targeted therapy. The diagnostic component is the Endotoxin Activity Assay (EAA™), which measures endotoxin activity in the bloodstream to identify patients who may benefit from intervention. The therapeutic component is Toraymyxin™ (PMX), a hemoadsorption device designed for the removal of endotoxins. Spectral is currently advancing Toraymyxin™ through the TIGRIS Phase 3 clinical trial in pursuit of U.S. FDA approval, aiming to provide an individualized approach to critical sepsis care. PMX is already approved for therapeutic use in Japan and Europe.

Recent filings

Filing Released Lang Actions
Notice of the meeting and record date - English.pdf
Regulatory Filings Classification · 1% confidence The document is a news release providing an update on a Management Cease Trade Order (MCTO) related to delays in filing annual regulatory documents due to continuance issues. It is not the full annual report or MD&A, nor an earnings release, proxy statement, or other specialized filing. It serves as a general regulatory announcement to investors about compliance status and next steps. Therefore, it best fits the “Regulatory Filings” fallback category (RNS).
2026-04-01 English
Notice of the meeting and record date - English.pdf
Regulatory Filings Classification · 1% confidence The document is a notice filed by Computershare to Canadian securities regulators providing logistical details for Spectral Medical Inc.’s upcoming Annual General and Special Meeting (record date, meeting date, location, proxy delivery, NAA requirements, security details). It is not a full proxy statement (no proposals or explanatory materials), nor an AGM presentation, earnings release, or other defined category. This type of administrative notice to regulators falls under the general regulatory filings category (RNS).
2026-04-01 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a 'Form 52-109F2', which is a standard Canadian regulatory filing for the 'Certification of Interim Filings'. It is a legal attestation by the CFO regarding the accuracy and internal controls of the interim financial reports. Since it is a regulatory certification document that does not fit into the specific categories of financial reports, management discussions, or announcements, it falls under the 'Regulatory Filings' category.
2025-11-07 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a 'Form 52-109F2', which is a standard Canadian regulatory filing for the 'Certification of Interim Filings'. It is signed by the CEO and CFO to certify the accuracy of the interim financial report and MD&A. Since this is a regulatory certification document required by securities legislation and does not fit into the specific categories of financial reports, management presentations, or announcements, it is best classified as a Regulatory Filing (RNS).
2025-11-07 English
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is explicitly titled 'MANAGEMENT'S DISCUSSION & ANALYSIS' and covers the nine-month period ended September 30, 2025. It provides a detailed narrative explanation of the company's financial performance, strategic direction, clinical development programs, and business operations. This aligns perfectly with the definition of a Management's Discussion and Analysis (MDA) report, which is a standard component of interim financial reporting.
2025-11-07 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Condensed Interim Consolidated Financial Statements' for Spectral Medical Inc. for the period ending September 30, 2025. It contains comprehensive financial statements (Statement of Financial Position, Statement of Loss and Comprehensive Loss, Statement of Changes in Shareholders' Deficiency, and Statement of Cash Flow) along with detailed explanatory notes. This meets the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. 9M 2025
2025-11-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.